MONOCLONAL ANTIBODY REFERRAL FORM

Phone: 855.896.9254

Fax: 855.370.0086



PATIENT INFORMATION					PRESCRIBER INFORMATION				
Last Name	Last Name First Name		DOB	Nam	Name of Contact Sending Referral			Title	
						3			
Gender	Social Security #		Primary Language	Met	Preferred Contact ☐ Email Referral Contact Email Method (check ☐ Phone one) ☐ Fax				
Address		Offic	ce Phone		Office Fax				
City State		ZIP	Prac	Practice / Facility Name					
Allergies					Address				
Phone Height			Weight	City			State	ZIP	
Symptom Onset Date and Time of Day COVID			D Positive Date	Pres	Prescriber Name / Specialty				
INSURANCE INFORMATION									
Insurance Provider			Plan ID #		Eligible for Medicare				
Insured's Name			Relationship to Patient	If no	If no insurance, list driver's license number and state of issue				
					Please fax with	order form: Current Mo	edication List 8	Copy of Insurance Card	
ELIGIBILITY					MEDICATION ORDERS				
Exclusion Criteria: If patient meets any of the following, they are not eligible for treatment: • Hospitalized due to COVID-19 • Require oxygen therapy due to COVID-19 • Require an increase in baseline oxygen flow due to COVID-19 in those on chronic					*Due to the high prevalence of the Omicron variant, Sotrovimab is the current MAB of choice for COVID-19 Therapy. REGEN-COV and Bam/Ete are available but can only be dispensed per prescriber request. The patient must be notified by prescriber prior to infusion of the potential of Bam/Ete or REGEN-COV therapy to be less than effective.				
oxygen therapy due to underlying non-COVID-19 related comorbidity Inclusion Criteria: Patients must be >=12 years old (Age:), AND weigh >=40kg (Wt kg), AND be at high risk for progressing to severe COVID-19 or					*Casirivimab and Imdevimab (REGEN-COV): 600 mg / 600 mg IV x 1 dose Directions: Infuse IV over 30 minutes per manufacturer guidelines.				
hospitalization.			neck all that apply) •		□ *Bamlanivimab and Etesevimab: 700 mg / 1.4 gm IV x 1 dose Directions: Infuse IV over 30 minutes per manufacturer guidelines. □ *Sotrovimab: 500mg: Directions: Infuse IV over 30 minutes per manufacturer guidelines.				
☐ Older age (i.e. >= 65 Ye		atrics >85th%])						
☐ Pregnancy					■ 50ml Sodium Chloride 0.9% Once infusion complete, flush the line with 50ml				
Chronic Kidney Disease					0.9% Sodium Chloride.				
☐ Diabetes					Flush line with D5W, 0.9% NaCl and/or Heparin 10 units/ml or 100 units/ml per Amber Specialty Pharmacy protocol.				
☐ Immunosuppressive Disease or Treatment					Amber Specialty Pharmacy protocol. Anaphylaxis Kit per Amber Specialty Pharmacy Home Infusion anaphylaxis				
Chronic Lung Disease					treatment protocol.				
☐ Sickle Cell Disease					Indiante IV seess types				
☐ Cardiovascular disease or hypertension					Indicate IV access type:				
Medical-related Technological Dependence (for example tracheostomy, gastrostomy, or positive pressure ventilation (unrelated to COVID-19))					Prophylaxis: Dose: Route:				
	other conditions that confer omes and severe congenital	_ I _	Indicate vaccination status: □ Unvaccinated □ Partially Vaccinated □ Fully Vaccinated □ Boosted						
☐ Other (please specify) ☐ Unvaccinated ☐ Partially Vaccinated ☐ Fully Vaccinated ☐ Boo									
Nursing Orders					SIGNATURE				
RN to insert peripheral IV or a RN to observe patient for 1 ho			r.						
RN to complete patient assessment					criber Signature			Date	

Please Print Name

REV 0122